Vaxart (NASDAQ: VXRT) is a coronavirus vaccine drugmaker that has polarized investors for much of the last year. If you bought its stock in January 2020, your investment would be up a whopping 500% over the past 12 months -- and at one point, it would have boasted returns as high as 1,500%. But those who bought at that high point would currently be sitting on an ugly 61% loss.
The controversy surrounding Vaxart stems entirely from its ability to bring a coronavirus vaccine to market. Is the company on track to complete such an achievement? Let's find out below.
Image source: Getty Images.
Source Fool.com